Search

Your search keyword '"Feng, Lisa"' showing total 21 results
Start Over Author "Feng, Lisa"
21 results on '"Feng, Lisa"'

1. Severe outcomes following pediatric cannabis intoxication: a prospective cohort study of an international toxicology surveillance registry

Author

Cohen, Neta, primary, Mathew, Mathew, additional, Brent, Jeffrey, additional, Wax, Paul, additional, Davis, Adrienne L., additional, Obilom, Cherie, additional, Burns, Michele M., additional, Canning, Joshua, additional, Baumgartner, Kevin, additional, Koons, Andrew L., additional, Wiegand, Timothy J., additional, Judge, Bryan, additional, Hoyte, Christopher, additional, Chenoweth, James A., additional, Froberg, Blake, additional, Farrar, Henry, additional, Carey, Jennifer L., additional, Hendrickson, Robert G., additional, Hodgman, Michael, additional, Caravati, E. Martin, additional, Christian, Michael R., additional, Wolk, Brian J., additional, Seifert, Steven A., additional, Bentur, Yedidia, additional, Levine, Michael, additional, Farrugia, Lynn A., additional, Vearrier, David, additional, Minns, Alicia B., additional, Kennedy, Joseph M., additional, Kirschner, Ron I., additional, Aldy, Kim, additional, Schuh, Suzanne, additional, Campleman, Sharan, additional, Li, Shao, additional, Myran, Daniel T., additional, Feng, Lisa, additional, Freedman, Stephen B., additional, and Finkelstein, Yaron, additional

Published
2023
Full Text
View/download PDF

6. Predicting pediatric esophageal wall thickness: An EUS study

Author

Rabinowitz, SimonS, primary, Grossman, Evan, additional, Feng, Lisa, additional, Ebigbo, Nonyelum, additional, Lin, Bo, additional, Gupta, Raavi, additional, Sklar, Rachel, additional, Schwarz, StevenM, additional, Weedon, Jeremy, additional, and Gress, Frank, additional

Published
2020
Full Text
View/download PDF

12. Discovery of Novel Oral Protein Synthesis Inhibitors of Mycobacterium tuberculosis That Target Leucyl-tRNA Synthetase

Author

Palencia, Andrés, primary, Li, Xianfeng, additional, Bu, Wei, additional, Choi, Wai, additional, Ding, Charles Z., additional, Easom, Eric E., additional, Feng, Lisa, additional, Hernandez, Vincent, additional, Houston, Paul, additional, Liu, Liang, additional, Meewan, Maliwan, additional, Mohan, Manisha, additional, Rock, Fernando L., additional, Sexton, Holly, additional, Zhang, Suoming, additional, Zhou, Yasheen, additional, Wan, Baojie, additional, Wang, Yuehong, additional, Franzblau, Scott G., additional, Woolhiser, Lisa, additional, Gruppo, Veronica, additional, Lenaerts, Anne J., additional, O'Malley, Theresa, additional, Parish, Tanya, additional, Cooper, Christopher B., additional, Waters, M. Gerard, additional, Ma, Zhenkun, additional, Ioerger, Thomas R., additional, Sacchettini, James C., additional, Rullas, Joaquín, additional, Angulo-Barturen, Iñigo, additional, Pérez-Herrán, Esther, additional, Mendoza, Alfonso, additional, Barros, David, additional, Cusack, Stephen, additional, Plattner, Jacob J., additional, and Alley, M. R. K., additional

Published
2016
Full Text
View/download PDF

14. Discovery of a Novel Class of Boron-Based Antibacterials with Activity against Gram-Negative Bacteria

Author

Hernandez, Vincent, primary, Crépin, Thibaut, additional, Palencia, Andrés, additional, Cusack, Stephen, additional, Akama, Tsutomu, additional, Baker, Stephen J., additional, Bu, Wei, additional, Feng, Lisa, additional, Freund, Yvonne R., additional, Liu, Liang, additional, Meewan, Maliwan, additional, Mohan, Manisha, additional, Mao, Weimin, additional, Rock, Fernando L., additional, Sexton, Holly, additional, Sheoran, Anita, additional, Zhang, Yanchen, additional, Zhang, Yong-Kang, additional, Zhou, Yasheen, additional, Nieman, James A., additional, Anugula, Mahipal Reddy, additional, Keramane, El Mehdi, additional, Savariraj, Kingsley, additional, Reddy, D. Shekhar, additional, Sharma, Rashmi, additional, Subedi, Rajendra, additional, Singh, Rajeshwar, additional, O'Leary, Ann, additional, Simon, Nerissa L., additional, De Marsh, Peter L., additional, Mushtaq, Shazad, additional, Warner, Marina, additional, Livermore, David M., additional, Alley, M. R. K., additional, and Plattner, Jacob J., additional

Published
2013
Full Text
View/download PDF

15. Inhibition of Toll-Like Receptor-Mediated Inflammation In Vitro and In Vivo by a Novel Benzoxaborole

Author

Dong, Chen, primary, Sexton, Holly, additional, Gertrudes, Ana, additional, Akama, Tsutomu, additional, Martin, Shamra, additional, Virtucio, Charlotte, additional, Chen, Chiao-Wen, additional, Fan, Xiaoqin, additional, Wu, Anne, additional, Bu, Wei, additional, Liu, Liang, additional, Feng, Lisa, additional, Jarnagin, Kurt, additional, and Freund, Yvonne R., additional

Published
2012
Full Text
View/download PDF

17. Discovery of Novel Oral Protein Synthesis Inhibitors of Mycobacterium tuberculosisThat Target Leucyl-tRNA Synthetase

Author

Palencia, Andrés, Li, Xianfeng, Bu, Wei, Choi, Wai, Ding, Charles Z., Easom, Eric E., Feng, Lisa, Hernandez, Vincent, Houston, Paul, Liu, Liang, Meewan, Maliwan, Mohan, Manisha, Rock, Fernando L., Sexton, Holly, Zhang, Suoming, Zhou, Yasheen, Wan, Baojie, Wang, Yuehong, Franzblau, Scott G., Woolhiser, Lisa, Gruppo, Veronica, Lenaerts, Anne J., O'Malley, Theresa, Parish, Tanya, Cooper, Christopher B., Waters, M. Gerard, Ma, Zhenkun, Ioerger, Thomas R., Sacchettini, James C., Rullas, Joaquín, Angulo-Barturen, Iñigo, Pérez-Herrán, Esther, Mendoza, Alfonso, Barros, David, Cusack, Stephen, Plattner, Jacob J., and Alley, M. R. K.

Abstract

ABSTRACTThe recent development and spread of extensively drug-resistant and totally drug-resistant resistant (TDR) strains of Mycobacterium tuberculosishighlight the need for new antitubercular drugs. Protein synthesis inhibitors have played an important role in the treatment of tuberculosis (TB) starting with the inclusion of streptomycin in the first combination therapies. Although parenteral aminoglycosides are a key component of therapy for multidrug-resistant TB, the oxazolidinone linezolid is the only orally available protein synthesis inhibitor that is effective against TB. Here, we show that small-molecule inhibitors of aminoacyl-tRNA synthetases (AARSs), which are known to be excellent antibacterial protein synthesis targets, are orally bioavailable and effective against M. tuberculosisin TB mouse infection models. We applied the oxaborole tRNA-trapping (OBORT) mechanism, which was first developed to target fungal cytoplasmic leucyl-tRNA synthetase (LeuRS), to M. tuberculosisLeuRS. X-ray crystallography was used to guide the design of LeuRS inhibitors that have good biochemical potency and excellent whole-cell activity against M. tuberculosis. Importantly, their good oral bioavailability translates into in vivoefficacy in both the acute and chronic mouse models of TB with potency comparable to that of the frontline drug isoniazid.

Published
2016
Full Text
View/download PDF

18. Inhibition of Toll-Like Receptor-Mediated Inflammation In Vitro and In Vivo by a Novel Benzoxaborole▪

Author

Dong, Chen, Sexton, Holly, Gertrudes, Ana, Akama, Tsutomu, Martin, Shamra, Virtucio, Charlotte, Chen, Chiao-Wen, Fan, Xiaoqin, Wu, Anne, Bu, Wei, Liu, Liang, Feng, Lisa, Jarnagin, Kurt, and Freund, Yvonne R.

Abstract

Pro-inflammatory cytokines play a critical role in the development of autoimmune and inflammatory diseases. Targeting the cytokine environment has proven efficient for averting inflammation. In this study, we reported that 6-[4-(aminomethyl)-2-chlorophenoxyl]benzo[c][1,2]oxaborol-1(3H)-ol (AN3485), a benzoxaborole analog, inhibited TLR2-, TLR3-, TLR4-, and TLR5-mediated TNF-α, IL-1β, and IL-6 release from human PBMCs and isolated monocytes with IC50values ranging from 18 to 580 nM, and the inhibition was mediated at the transcriptional level. Topical administration of AN3485 significantly reduced PMA-induced contact dermatitis and oxazolone-induced delayed-type hypersensitivity in mice, indicating its capability of penetrating skin and potential topical application in skin inflammation. Oral administration of AN3485 showed dose-dependent suppression of LPS-induced TNF-αand IL-6 production in mice with an ED90of 30 mg/kg. Oral AN3485, 35 mg/kg, twice a day, suppressed collagen-induced arthritis in mice over a 20-day period. The potent anti-inflammatory activity in in vitro and in vivo disease models makes AN3485 an attractive therapeutic lead for a variety of cutaneous and systemic inflammatory diseases.

Published
2013
Full Text
View/download PDF

19. Discovery of a Novel Class of Boron-Based Antibacterials with Activity against Gram-Negative Bacteria

Author

Hernandez, Vincent, Crépin, Thibaut, Palencia, Andrés, Cusack, Stephen, Akama, Tsutomu, Baker, Stephen J., Bu, Wei, Feng, Lisa, Freund, Yvonne R., Liu, Liang, Meewan, Maliwan, Mohan, Manisha, Mao, Weimin, Rock, Fernando L., Sexton, Holly, Sheoran, Anita, Zhang, Yanchen, Zhang, Yong-Kang, Zhou, Yasheen, Nieman, James A., Anugula, Mahipal Reddy, Keramane, El Mehdi, Savariraj, Kingsley, Reddy, D. Shekhar, Sharma, Rashmi, Subedi, Rajendra, Singh, Rajeshwar, O'Leary, Ann, Simon, Nerissa L., De Marsh, Peter L., Mushtaq, Shazad, Warner, Marina, Livermore, David M., Alley, M. R. K., and Plattner, Jacob J.

Abstract

ABSTRACTGram-negative bacteria cause approximately 70% of the infections in intensive care units. A growing number of bacterial isolates responsible for these infections are resistant to currently available antibiotics and to many in development. Most agents under development are modifications of existing drug classes, which only partially overcome existing resistance mechanisms. Therefore, new classes of Gram-negative antibacterials with truly novel modes of action are needed to circumvent these existing resistance mechanisms. We have previously identified a new a way to inhibit an aminoacyl-tRNA synthetase, leucyl-tRNA synthetase (LeuRS), in fungi via the oxaborole tRNA trapping (OBORT) mechanism. Herein, we show how we have modified the OBORT mechanism using a structure-guided approach to develop a new boron-based antibiotic class, the aminomethylbenzoxaboroles, which inhibit bacterial leucyl-tRNA synthetase and have activity against Gram-negative bacteria by largely evading the main efflux mechanisms in Escherichia coliand Pseudomonas aeruginosa. The lead analogue, AN3365, is active against Gram-negative bacteria, including Enterobacteriaceaebearing NDM-1 and KPC carbapenemases, as well as P. aeruginosa. This novel boron-based antibacterial, AN3365, has good mouse pharmacokinetics and was efficacious against E. coliand P. aeruginosain murine thigh infection models, which suggest that this novel class of antibacterials has the potential to address this unmet medical need.

Published
2012
Full Text
View/download PDF

21. EHRs in primary care practices: benefits, challenges, and successful strategies.

Author

Goetz Goldberg D, Kuzel AJ, Feng LB, DeShazo JP, and Love LE

Subjects
American Recovery and Reinvestment Act, Efficiency, Organizational, Electronic Health Records economics, Group Practice, Humans, Inservice Training, Interviews as Topic, Primary Health Care standards, Primary Health Care trends, Private Practice, Qualitative Research, Quality Assurance, Health Care standards, Staff Development, United States, Virginia, Attitude of Health Personnel, Electronic Health Records organization & administration, Primary Health Care organization & administration, Quality Assurance, Health Care methods
Abstract

Objectives: To understand the current use of electronic health records (EHRs) in small primary care practices and to explore experiences and perceptions of physicians and staff toward the benefits, challenges, and successful strategies for implementation and meaningful use of advanced EHR functions., Study Design: Qualitative case study of 6 primary care practices in Virginia., Methods: We performed surveys and in-depth interviews with clinicians and administrative staff (N = 38) and observed interpersonal relations and use of EHR functions over a 16-month period. Practices with an established EHR were selected based on a maximum variation of quality activities, location, and ownership., Results: Physicians and staff report increased efficiency in retrieving medical records, storing patient information, coordination of care, and office operations. Costs, lack of knowledge of EHR functions, and problems transforming office operations were barriers reported for meaningful use of EHRs. Major disruption to patient care during upgrades and difficulty utilizing performance tracking and quality functions were also reported. Facilitators for adopting and using advanced EHR functions include team-based care, adequate technical support, communication and training for employees and physicians, alternative strategies for patient care during transition, and development of new processes and work flow procedures., Conclusions: Small practices experience difficulty with implementation and utilization of advanced EHR functions. Federal and state policies should continue to support practices by providing technical assistance and financial incentives, grants, and/or loans. Small practices should consider using regional extension center services and reaching out to colleagues and other healthcare organizations with similar EHR systems for advice and guidance.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results